Literature DB >> 1555686

Pulsatile luteinizing hormone secretion in hypothalamic amenorrhea, anorexia nervosa, and polycystic ovarian disease during naltrexone treatment.

M C Armeanu1, G M Berkhout, J Schoemaker.   

Abstract

OBJECTIVE: To determine if chronic treatment with the long-acting oral opioid antagonist naltrexone can increase luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion in women with secondary amenorrhea.
DESIGN: Prospective.
SETTING: Large reproductive endocrinology unit of an academic hospital. PATIENTS: Three groups of women with oligomenorrhea or amenorrhea: (1) hypothalamic amenorrhea; (2) anorexia nervosa; and (3) polycystic ovarian disease (PCOD). INTERVENTION: Naltrexone 50 mg every day for 4 days. MAIN OUTCOME MEASURES: Luteinizing hormone pulse pattern, frequency and amplitude, mean LH and FSH levels, measured by serial blood sampling over a 6-hour period before and after naltrexone.
RESULTS: Naltrexone caused a significant increase (P less than 0.05) of the LH pulse frequency in patients with hypothalamic amenorrhea and in PCOD but not in anorexia nervosa. The mean levels of LH and FSH and LH pulse amplitudes were not significantly changed by naltrexone. The naltrexone nonresponders were underweight either because of simple weight loss or anorexia nervosa and had low levels of estradiol and an LH pulse pattern similar to the luteal one.
CONCLUSION: The luteal LH pulse pattern in weight loss-related amenorrhea is caused by a nonopioid, undernutrition-linked factor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555686     DOI: 10.1016/s0015-0282(16)54956-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

1.  A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.

Authors:  Erin Kelty; Gary Hulse
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

2.  Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.

Authors:  A M Fulghesu; M Ciampelli; C Belosi; R Apa; M Guido; A Caruso; S Mancuso; A Lanzone
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

3.  Astressin B, a nonselective corticotropin-releasing hormone receptor antagonist, prevents the inhibitory effect of ghrelin on luteinizing hormone pulse frequency in the ovariectomized rhesus monkey.

Authors:  Nicolas R Vulliémoz; Ennian Xiao; Linna Xia-Zhang; Jean Rivier; Michel Ferin
Journal:  Endocrinology       Date:  2007-12-06       Impact factor: 4.736

4.  Discovery of potent kisspeptin antagonists delineate physiological mechanisms of gonadotropin regulation.

Authors:  Antonia K Roseweir; Alexander S Kauffman; Jeremy T Smith; Kathryn A Guerriero; Kevin Morgan; Justyna Pielecka-Fortuna; Rafael Pineda; Michelle L Gottsch; Manuel Tena-Sempere; Suzanne M Moenter; Ei Terasawa; Iain J Clarke; Robert A Steiner; Robert P Millar
Journal:  J Neurosci       Date:  2009-03-25       Impact factor: 6.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.